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The DOT1L rs12982744
polymorphism is associated with
osteoarthritis of the hip with
genome-wide statistical
signiﬁcance in males
Osteoarthritis (OA) of the hip is a major cause of pain, disabil-
ity and use of healthcare resources.1 Although OA is multifac-
torial, it is known to have signiﬁcant genetic contribution and
a number of studies have attempted to dissect such contribu-
tion (see2 for review).
The DOT1L gene encodes the DOT1-like histone H3 methyl-
transferaseis, a potentially dedicated enzyme for Wnt target
gene activation in leukaemia recently shown to be associated
with endochondral bone formation.3
A polymorphism (rs12982744) in DOT1L has been found to
be strongly associated with minimum joint space width
(minJSW) at the hip. This exact same single nucleotide poly-
morphism (SNP) was previously identiﬁed to be associated
with increased height.4 5 The C allele associated with lower
minJSW and lower height was associated with hip OA,
although this association did not reach genome-wide signiﬁ-
cance (GWS) (OR 1.14, CI 1.06 to 1.22; p=1.5× 10−4).3
The GWS level of p<5×10−8 is the threshold at which
genetic associations are considered credible.6 The aim of our
study was to prove that common genetic variation in the
DOT1L gene is important in hip OA at this level of conﬁdence.
Genetic association data for rs12982744 and hip OA were
derived from the Translational Research in Europe Applied
Technologies for OsteoArthritis (TREAT-OA) consortium and
combined with data from the UK (arcOGEN consortium),
Estonia (Estonian Genome Center of the University of Tartu)
and other studies (Nottingham, GOAL).3 The total sample size
was 9789 hip OA cases and 31 873 controls of which there
were 4155 cases and 15 213 controls in male subjects and 5634
cases and 16 660 controls in female subjects. Summary OR was
calculated using a ﬁxed effects model. The individual study esti-
mates and sample sizes are shown in ﬁgure 1. A full detailed
description of each study cohort on recruitment, radiographic
and clinical assessment is found in.7 8 Studies were approved
by the relevant Ethics Committee and informed consent was
obtained from all study participants.
The results of the meta-analysis show that in male subjects
the C allele of DOT1L rs12982744 is GWS with a 17% increased
risk of hip OA (OR 1.17, 95% CI 1.11 to 1.23, p=7.8×10−9) with
no observed heterogeneity (I2=0). In female subjects, the OR is
1.05 (95% CI 1.00 to 1.10, p=0.04) with I2=31%. The effect size
estimate is signiﬁcantly different between both sexes (p=0.003)
with non-overlapping CIs. For both genders combined, the p
value was 8.1×10−8 (I2=35%) (ﬁgure 1). The difference in effect
size between genders is not surprising considering the sexual
dimorphism of this trait: men have a larger mJSWand prevalence
of hip OA rises speciﬁcally in women after menopause, suggest-
ing a role of sex hormones in the disease process.
In this large-scale meta-analysis we show that the associ-
ation between a DOT1L SNP and hip OA achieves GWS in
male subjects strengthening the robustness of DOT1L as a risk
factor for hip OA.
This makes DOT1L a potential therapeutic target for modu-
lation and intervention in hip OA. This is relevant since small
molecular inhibitors have been developed and a phase I trial
has been started (http://epizyme.com/programs/dot1l.asp).
This result also highlights the greater statistical power of
quantitative endophenotypes for genetic studies.
Figure 1 Forest plot of study-speciﬁc estimates and ﬁxed effects summary OR estimates and 95% CIs for the association between the C allele and
the rs12982744 polymorphism of the DOT1L gene and hip osteoarthritis. Analyses were carried out using Stata V.12 (College Station, Texas, USA).
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